IndexNo:810321:RdnEroepwgoNKIz
| 投稿者 | Alexandra |
|---|---|
| 投稿日時 | 2014/08/11 23:07:28 |
| What do you do for a living? http://www.tecnnova.org/papers-written/ essay on friends Gilotrif's approval was based on a clinical study of 345 patients who were randomly assigned to receive either Gilotrif or up to six cycles of the chemotherapy drugs pemetrexed and cisplatin. Patients who received Gilotrif had a delay in tumor growth (progression-free survival) that was more than four months longer than those who received chemotherapy. However, there was no statistically significant difference in overall survival between the two groups of patients, the FDA said. | |